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Abstract
Pulmonary embolism is sudden occlusion of pulmonary arteries, usually by a clot aris-
ing in the lower limb veins. The majority of pulmonary emboli are silent, and it is only 
when the embolus burden is substantial that the patient becomes symptomatic. Mortality 
after an acute, major thromboembolic episode is significantly high. Pulmonary embolism 
which causes hemodynamic instability is usually associated with occlusion of more than 
50% of the pulmonary vasculature. Associated severe pulmonary hypertension may cause 
cardiac arrest. The precipitation of RV failure is also affected by the degree of preexisting 
right ventricular hypertrophy or dilatation, tricuspid valve regurgitation, and the pres-
ence of coronary artery disease. Aggressive therapy is needed in this subgroup of patients. 
Unfortunately, surgical embolectomy is seldom even entertained as an option in the man-
agement of these patients. A critical assessment of the data reveals that there is in fact a 
definite place for surgical therapy in the management of massive pulmonary embolism.
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1. Introduction
Pulmonary embolism is sudden occlusion of pulmonary arteries, usually by a clot arising 
in the lower limb veins. It is not a disease by itself but rather a complication of this venous 
thrombosis.
Pulmonary embolism is commonly mislabeled, more likely an unrecognized phenomenon 
particularly in hospitalized individuals.
The majority of pulmonary emboli are silent, and it is only when the embolus burden is sub-
stantial that the patient becomes symptomatic. Mortality after an acute, major thromboem-
bolic episode reaches about 15–20% of patients within 48 hours [1].
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Aggressive therapy is needed in this subgroup of patients. Unfortunately, surgical embolec-
tomy is seldom even entertained as an option in the management of these patients, published 
mortality rates for acute pulmonary embolectomy have ranged from 20 to 60%, making it 
difficult to argue that the surgical results were any better than the natural history. A critical 
assessment of the data reveals that there is in fact a definite place for surgical therapy in the 
management of massive pulmonary embolism [2].
2. Practice essentials
Pulmonary embolism usually presents with dyspnea, tachypnea, dull chest pain, and cardio-
vascular changes such as tachycardia, mild-to-moderate hypotension, and distended neck 
veins. Most pulmonary embolism patients are hemodynamically stable and have adequate 
cardiac output.
Pulmonary embolism which causes hemodynamic instability is termed massive pulmonary 
embolism. It is usually associated with occlusion of more than 50% of the pulmonary vascula-
ture [3]. Pulmonary angiograms demonstrate a unique degree of blockage of the pulmonary 
vasculature.
The severity of symptoms may not be related to the embolus burden, particularly in patients 
with preexisting cardiac or pulmonary disease. Cardiac arrest may occur. The precipitation of 
RV failure is also affected by the degree of right ventricular hypertrophy or dilatation, tricus-
pid valve regurgitation, and the presence of coronary artery disease. Pulmonary hypertension 
is also influenced by many factors. Humoral factors such as serotonin, adenosine diphosphate 
(ADP), platelet-derived growth factor (PDGF), and thromboxane are released from platelets 
attached to the thrombi. Anoxia and tissue ischemia downstream from emboli inhibit endo-
thelium-derived relaxing factor (EDRF) production and enhance release of superoxide anions 
by activated neutrophils [4].
2.1. Anatomy
The anatomy of the pulmonary vasculature should be familiar to all cardiothoracic surgeons. 
What may be less well appreciated, however, is the remarkable access available to the lobar 
vessels via median sternotomy. All lobar and segmental vessels can be accessed via incisions 
in the pulmonary arteries from within the pericardial space as one would during pulmonary 
thrombo-endarterectomy [5].
2.2. Pathophysiology
Pathophysiology of pulmonary hypertension in acute pulmonary embolism entails the 
release of serotonin from platelets, histamine from tissues, and circulating thrombin. Hypoxia 
due to ventilation/perfusion mismatch and increased dead space will also worsen pulmonary 
vasoconstriction and set a vicious cycle. Persistent systemic hypotension or refractory hypox-
emia is an indication for aggressive interventional, surgical, or thrombolytic management. 
Operative risk is markedly elevated once the patient is in cardiogenic shock [6].
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Right ventricular dysfunction is a harbinger of hemodynamic decompensation, an event that 
may unfold quite precipitously, abruptly closing the window of opportunity on a patient 
that has been otherwise holding on for several hours. Thrombolytics have taken center stage 
in the aggressive treatment of the unstable patient [7]. This is in part due to their wide avail-
ability and the familiarity many physicians have with their use in the context of treating acute 
coronary syndromes. However, study reports found no improvement in mortality rate when 
thrombolytics were used in unselected patients as compared with heparin but an almost two-
fold increased risk of hemorrhage. Catheter embolectomy is another option. Endovascular 
techniques include clot fragmentation, clot aspiration, and rheolytic therapy. The mortality 
rate associated with these interventions, however, has been 25–30% [8]. Surgical intervention 
performed before hemodynamic collapse has an operative risk no higher than that of throm-
bolytic therapy in most cases. Surgery is clearly the option of choice when there is a clot in 
transit, in the right atrium, or trapped in a patent foramen ovale [7, 9].
3. Diagnosis
Diagnosis is suspected with a history consistent with massive pulmonary embolism. Symptoms 
and signs vary with the extent of blockage, the magnitude of humoral response, and the car-
diac and pulmonary reserve of the patient. Routine laboratory tests are usually normal. Serum 
D-dimer is almost always elevated in the presence of acute pulmonary embolus and is frequently 
used in emergency rooms as a screening test. The most common electrocardiographic abnormali-
ties of acute pulmonary embolism are tachycardia and nonspecific ST- and T-wave changes [5]. 
The major value of the electrocardiogram is excluding a myocardial infarction. A minority of 
patients with massive embolism may show evidence of corpulmonale, right axis deviation, or 
right bundle branch block. Chest X-ray may show oligemia (Westermark’s sign) or linear atelec-
tasis (Fleischner lines), both of which are nonspecific findings. Ventilation-perfusion (V/Q) scans 
may be used for their negative predictive value and may be unreliable because of pneumonia, 
atelectasis, previous pulmonary emboli, and other conditions may cause a ventilation and per-
fusion mismatch. In general, negative V/Q scan may rule out significant pulmonary embolism. 
Pulmonary angiogram provides the most definitive diagnosis for acute pulmonary embolism. 
Contrast-enhanced high-resolution computerized tomographic (CT) scanning is most commonly 
diagnostic (Figure 1).
Advantages of MDCTPA in the diagnosis of acute PE are as follows:
• Widely available, especially after day hours
• Rapid interpretation
• Direct visualization of embolus
• Noninvasive
• Highly accurate
• Evaluation of alternative causes of chest pain
• Possible concurrent performance of lower extremity
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• venous imaging with CTV
• Ability to provide ancillary findings, which may affect management and prognosis [CTV 
(computed tomographic venography) and MDCTPA (multidetector computed tomograph-
ic pulmonary angiography)].
The most important recent diagnostic development from a surgical standpoint is transesopha-
geal echocardiography. This modality may not visualize distal embolic material in the pulmo-
nary vasculature but is more important to identify thrombus in transit, including paradoxical 
embolus in transit, and to permit evaluation of right ventricular function (Figure 2) [10].
4. Treatment
Oxygen should be administered to alleviate hypoxic pulmonary vasoconstriction, and it is likely 
that a severely affected patient will require intubation and ventilator support. Pharmacological 
agents, including vasopressors, may be instituted to stabilize the patient.
Pulmonary artery catheters, although obviously helpful in management, may occasionally 
emboli more thrombi because of the risk of dislodging further thromboembolic material [11].
4.1. Thrombolysis
Natural history of the clot in survivors of acute embolic events is fragmentation and pro-
gressive lysis. Thrombolytic agents dissolve thrombi by activating plasminogen to plasmin. 
Figure 1. Massive PE as appears in contrast enhanced CT chest.
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Plasmin, when in proximity to a thrombus, degrades fibrin to soluble peptides. Circulating 
plasmin also degrades soluble fibrinogen and, to variable degrees, factors II, V, and VIII. In 
addition, increased concentrations of fibrin and fibrinogen degradation products contrib-
ute to coagulopathy by both inhibiting the conversion of fibrinogen to fibrin and interfering 
with fibrin polymerization. The thrombolytic agents currently reported for the treatment of 
acute pulmonary embolism include streptokinase, urokinase, recombinant tissue plasmin-
ogen activator (rt-PA, alteplase), anisoylated plasminogen streptokinase activator complex 
(APSAC, anistreplase), and reteplase [12]. There are newer agents arriving, like tenecteplase, 
lanoteplase, staphylokinase, and saruplase and are undergoing clinical testing.
Trials suggest a trend toward better results with thrombolytic therapy because of a more rapid 
diminution in right ventricular afterload and dysfunction. Compared with heparin therapy 
alone, thrombolytic agents carry a higher risk of bleeding problems, with up to 20% of patients 
experiencing a significant bleeding complication [13]. In general, thrombolytic therapy is con-
traindicated in patients with fresh surgical wounds, anemia, recent stroke, peptic ulcer, or 
bleeding dyscrasias.
4.2. Anticoagulation
Patients should be heparinized to prevent further propagation of thrombus at its origin and 
also in the pulmonary arterial tree. Intravenous (IV) heparin is started with an initial bolus dose 
of 70 U/kg followed by 18–20 U/kg/h. Heparin prevents propagation and formation of new 
thrombus. It rarely dissolves existing clot. Intrinsic fibrinolytic system will lyse fresh thrombi 
over a period of days to weeks. Evidence suggests early treatment of stable patients with acute 
pulmonary embolism with subcutaneous low-molecular-weight heparin (tinzaparin) given 
Figure 2. Echocardiogram demonstrating thrombus in transit across PFO.
Pulmonary Embolism
http://dx.doi.org/10.5772/68040
51
once daily has been shown to be as effective and safe as IV heparin with respect to recurrent 
thromboembolism, major bleeding, and death [14].
4.3. Surgical embolectomy
Emergency pulmonary embolectomy was first described by Trendelenburg in 1908, using 
pulmonary artery and aortic occlusion, through a transthoracic approach. There were no 
surviving patients [14]. Later on, the first successful open embolectomy was performed and 
described by Sharp using cardiopulmonary bypass [15].
If a patient has been taken directly to the operating room without a definitive diagnosis, trans-
esophageal or epicardial echocardiography and color Doppler mapping can confirm or refute 
the diagnosis in the operating room.
4.3.1. Indication for surgery
Emergency pulmonary thromboembolectomy is indicated for suitable patients with life-
threatening circulatory insufficiency, where the diagnosis of acute pulmonary embolism has 
been established. Indications for acute surgical intervention include the following: hemo-
dynamic instability, definitive diagnosis of pulmonary embolism in the main or lobar pul-
monary arteries with compromise of gas exchange, unstable patients in whom thrombolytic 
or anticoagulation therapy is absolutely contraindicated, thrombus in transit or thrombus 
trapped within the right atrium, patent foramen ovale, or right ventricle.
Surgical embolectomy, as initial therapy for massive PE compared to thrombolytic therapy, 
has less early mortality rates and significantly less bleeding complications.
Patients who undergo surgical embolectomy after the failure of lysis clearly demonstrate a 
critically high-mortality rate.
CT-derived RV/LV ratio could be a useful parameter to identify candidates who might benefit 
from direct surgical therapy instead of thrombolysis [16].
4.3.2. Operative procedure
Intraoperative transesophageal echocardiography is now a routine in modern practice and 
greatly facilitates intraoperative decision-making particularly with regard to exploration of 
the right atrium and evaluation for clot in transit [10]. The groin vessels should be prepped 
into the field in case postoperative extracorporeal membrane oxygenation is necessary. Poor 
venous return from the inferior vena cava line only can be a result of clot in transit impacted 
in the cannula orifice (Figure 3). For this reason, the superior vena cava cannula is placed first 
so that partial bypass may be initiated if clot is dislodged from the inferior vena cava. Routine 
massage of the lower extremities and abdomen and open aspiration of the inferior vena cava 
return with cardiotomy suckers is better to extract additional material in transit. Tapes are 
passed around the superior vena cava and inferior vena cava, if patent foramen ovale or para-
doxic embolus in transit has been identified by transesophageal echo. A brief episode of car-
dioplegic arrest should be instituted to examine the left atrium (Figure 4).
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If embolus in transit is identified in the right atrium, this can be extracted via a standard right 
atrial incision without cardioplegic arrest (Figure 4). This approach provides optimal protec-
tion of the right ventricle during the procedure. If right atrial exploration is not required, 
Figure 3. The pulmonary arteriotomy sites.
Figure 4. Approaches to explore thrombus in transit.
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a bullet-tip sucker can be dropped into the right atrium via a stab wound with a purse-string 
suture. This will reduce the amount of blood passing through the right ventricle and into the 
pulmonary artery [11, 17].
The pulmonary vessels are extraordinarily fragile and rapidly taper in diameter, making rup-
ture of the vessels a very real possibility. Thrombus in the left pulmonary artery is accessed 
via an incision beginning in the main pulmonary artery. Adequate access permitting direct 
visualization of the segmental vessels requires extension of the incision onto the left pul-
monary artery itself. This may require division of the pericardial reflection over the ventral 
surface of the pulmonary artery (Figure 5).
A linear incision first in the posterior pericardium overlying the vessel and then in the vessel 
itself provides ready access to all of the lobar and segmental vessels. An incision such as this per-
mits direct inspection of the right upper lobe branch, right middle lobe branch, and the segmen-
tal vessels to the right lower lobe. A flexible suction catheter passed in the pulmonary arteries 
with massage of the lungs, helps to dislodge smaller thrombi in the distal branches (Figure 6). 
The arteriotomies are primarily closed with running 4-0 Prolene. A final step in the procedure 
is insertion of an inferior vena cava filter via a purse-string suture on the right atrial appendage.
Figure 5. Incision to explore distal pulmonary arteries.
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4.3.3. Benefits of surgery
Pulmonary embolectomies demonstrate excellent early and late survival rates for patients 
with stable PE and unstable PE. These findings confirm pulmonary embolectomy as a benefi-
cial therapeutic option for central PE, especially during the postoperative period when throm-
bolytic therapy is often contraindicated. Procoagulant risk factors such as endothelial injury, 
malignancy, and decreased mobility are common among postoperative patient populations 
across surgical specialties, but surgical options for the treatment of PE remain underappreci-
ated and underutilized. With increasing surgical experience and improved outcomes, the role 
for pulmonary embolectomy in the acute setting may be expanding [18, 19]. All PE patients 
with imminent risk of hemodynamic decompensation due to severe RV impairment and 
central clot burden should be evaluated for surgical treatment [20]. Surgical embolectomy 
although normally confined to the most critical PE patients can be done with good long-
term survival comparable to active medical treatment with thrombolysis despite the mortality 
risk inflicted by the surgical procedure. High-risk PE patients treated with surgical embolec-
tomy had a significantly lower amount of residual emboli and pulmonary diffusion impair-
ment than patients treated with thrombolysis. The clinical consequences of residual emboli 
were identified significant shorter 6-MWT, a higher mean pulmonary arterial pressure, 
and more dyspnea when compared to PE patients without residual emboli [21]. Residual 
clot burden is an independent risk factor for increased mortality at long-term follow-up 
[22]. Residual emboli after acute PE were found to be an independent predictor for chronic 
thromboembolic pulmonary hypertension, a severe late complication of acute PE [21, 22]. 
Figure 6. Lung massage to mobilise peripheral thrombi.
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Pulmonary diffusion impairment after acute PE occurs more frequently in high-risk patients 
treated with thrombolysis compared to surgical embolectomy and was correlated with resid-
ual emboli. The surgical superiority on pulmonary morbidity is due to rapid removal of the 
total emboli resulting in fast restoration of normal pulmonary circulation, while thrombolysis 
either is unable to resolve the emboli due to its size or fractionates it into smaller parts which 
are carried to the peripheral pulmonary vasculature.
Current American Heart Association, European Society of Cardiology, and American College 
of Chest Physicians guidelines reserve surgical pulmonary embolectomy for central PE with 
hemodynamic instability and a contraindication for thrombolytic therapy, or when throm-
bolysis has failed [23, 24]. These treatment algorithms are based on limited data from small 
surgical series, and these practice patterns may be more reflective of scarce surgical expertise. 
Increasing evidence suggests that pulmonary embolectomy might be considered first-line 
therapy for select patients [25, 26]. This has resulted in the extension of eligibility for pulmo-
nary embolectomy to include those who are hemodynamically stable but with demonstrative 
evidence of impending right ventricular failure [27].
5. ECMO in pulmonary embolism
Extracorporeal membrane oxygenation use (ECMO) for selected patients with massive PE is 
associated with good outcomes. Patients presenting in cardiac arrest have worse outcomes. 
Survival rates and neurological recovery are better when the cause of cardiac arrest is pulmo-
nary embolism compared to other causes of cardiac arrest [11].
As an emergency procedure, standard femoro-femoral, venoarterial ECMO is instituted to 
ensure rapid and effective CPR in arrest or pre arrest patients, this can be achieved by use 
of smaller percutaneous cannulas limited to basic one arterial and one venous cannula 
(Figure 7) [5].
The tip of the venous catheter is advanced into the right atrium to obtain a flow rate of 2.5–4.0 l/
min using an emergency pump-oxygenator circuit primed with crystalloid.
Mortality rates for emergency pulmonary thromboembolectomy vary widely between 11 
and 92% in retrospective studies with varying operative techniques, preoperative hemo-
dynamic state of the patient populations, and treatment plans. In general, greater surgical 
mortality was encountered if a patient had a preoperative cardiac arrest or required ECMO 
support [9, 28].
Prevention of recurrence should always be stressed upon in patients with successful out-
comes, by addressing factors such as obesity, tobacco abuse, use of oral contraceptives, or 
postmenopausal hormone replacement. Consideration should be given to a search for occult 
malignancy. Consultation with a hematologist and systematic search for a prothrombotic 
state is routine. If no treatable cause is identifiable or patients have evidence of a hypercoagu-
lable state, warfarin therapy is indicated for life.
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